Nektar Therapeutics has been granted a patent for a method of cancer treatment involving the administration of a 4-1BB agonist and a long-acting, IL-2Rß-selective agonist. The patent also covers related compositions and kits for this therapeutic approach. GlobalData’s report on Nektar Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Nektar Therapeutics, Nanoparticle drug conjugates was a key innovation area identified from patents. Nektar Therapeutics's grant share as of July 2024 was 55%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent US12054553B2 outlines a method for administering a combination of immunotherapeutic agents to subjects diagnosed with cancer. The method involves administering a 4-1BB agonist alongside a long-acting interleukin-2 receptor beta (IL-2Rß)-preferential agonist, which is designed to activate the immune system. The claims specify various administration routes, including systemic and intravenous delivery for the 4-1BB agonist and the long-acting IL-2Rß-preferential agonist. Additionally, the patent allows for the simultaneous or separate administration of these agents with toll-like receptor agonists, which can be delivered directly to cancerous tissues, particularly solid tumors, through methods such as intratumoral or peritumoral injection.
The patent further details the specific types of agents that can be used, including antibodies that selectively bind to the 4-1BB receptor, such as urelumab and utomilumab, and a defined long-acting IL-2Rß-preferential agonist. The method is intended to enhance immune activation, targeting various immune cells like CD8 T cells and dendritic cells while suppressing regulatory T cells and other immunosuppressive cells. The claims also suggest that this combination therapy could produce an abscopal effect, where treatment at one site leads to tumor regression at distant sites, thereby offering a potential therapeutic strategy for a wide range of solid tumors, including breast, ovarian, and lung cancers, among others.
To know more about GlobalData’s detailed insights on Nektar Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
